The protein C pathway in intestinal barrier function: Challenging the hemostasis paradigm

Annals of the New York Academy of Sciences

Volumn 1258, Issue 1, 2012, Pages 78-85

  D'Alessio, Silvia ^a   Genua, Marco ^a   Vetrano, Stefania ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Activated PC; Coagulation; Inflammatory bowel disease (IBD); Intestinal barrier; Protein C

Indexed keywords

ACTIVATED PROTEIN C; CYTOKINE; DROTRECOGIN; PROTEIN C;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL SURVIVAL; COLITIS; CROHN DISEASE; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENTERITIS; HEMOSTASIS; HUMAN; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; LUNG FIBROSIS; LUNG INJURY; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SEPSIS; SIGNAL TRANSDUCTION; TIGHT JUNCTION; ULCERATIVE COLITIS; WOUND HEALING;

EID: 84862847964     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06557.x     Document Type: Article

References (83)

1. Esmon, C.T. 2006. Inflammation and the activated protein C anticoagulant pathway. Semin. Thromb. Hemost. 32: (Suppl 1) 49-60.
2. Danese, S. et al 2010. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 115: 1121-1130.
3. Esmon, C.T. 2002. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J. Exp. Med. 196: 561-564.
4. Okajima, K. 2004. Regulation of inflammatory responses by activated protein C: the molecular mechanism(s) and therapeutic implications. Clin. Chem. Lab. Med. 42: 132-141.
5. Conway, E.M. et al 2002. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J. Exp. Med. 196: 565-577.
6. Kurosawa, S., C.T. Esmon & D.J. Stearns-Kurosawa 2000. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J. Immunol. 165: 4697-4703.
7. Iwaki, T. et al 2005. A cardioprotective role for the endothelial protein C receptor in lipopolysaccharide-induced endotoxemia in the mouse. Blood 105: 2364-2371.
8. Murakami, K. et al 1997. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am. J. Physiol. 272(2 Pt 1): L197-L202.
9. Scaldaferri, F. et al 2007. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J. Clin. Invest. 117: 1951-1960.
10. Crawley, J.T., & M. Efthymiou 2008. Cytoprotective effect of activated protein C: specificity of PAR-1 signaling. J. Thromb. Haemost. 6: 951-953.
11. Vetrano, S. et al 2011. Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation. Proc. Natl. Acad. Sci. USA 108: 19830-19835.
12. Esmon, C.T., J. Stenflo & J.W. Suttie 1976. A new vitamin K-dependent protein. A phospholipid-binding zymogen of a serine esterase. J. Biol. Chem. 251: 3052-3056.
13. Esmon, C.T. 2003. The protein C pathway. Chest 124(3 Suppl): 26S-32S.
14. Stearns-Kurosawa, D.J. et al 1996. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc. Natl. Acad. Sci. USA 93: 10212-10216.
15. Kalafatis, M., M.D. Rand & K.G. Mann 1994. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J. Biol. Chem. 269: 31869-31880.
16. Nicolaes, G.A. et al 1995. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J. Biol. Chem. 270: 21158-21166.
17. Yegneswaran, S. et al 1997. Protein S alters the active site location of activated protein C above the membrane surface. A fluorescence resonance energy transfer study of topography. J. Biol. Chem. 272: 25013-25021.
18. Koeleman, B.P., P.H. Reitsma, C.F. Allaart & R.M. Bertina 1994. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 84: 1031-1035.
19. Macias, W.L., S.B. Yan, M.D. Williams, et al 2005. New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit. Care 9(Suppl 4): S38-S45.
20. Mizutani, A., K. Okajima, M. Uchiba & T. Noguchi 2000. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 95: 3781-3787.
21. Yuda, H. et al 2004. Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood 103: 2196-2204.
22. Grinnell, B.W. & D. Joyce 2001. Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis. Crit. Care. Med. 29(7 Suppl): S53-60; discussion S60-1.
23. Nick, J.A. et al 2004. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104: 3878-3885.
24. Schoots, I.G. et al 2004. Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats. Crit. Care. Med. 32: 1375-1383.
25. Isobe, H. et al 2004. Activated protein C reduces stress-induced gastric mucosal injury in rats by inhibiting the endothelial cell injury. J. Thromb. Haemost. 2: 313-320.
26. Suzuki, K. et al 2004. Protective role of activated protein C in lung and airway remodeling. Crit. Care. Med. 32(5 Suppl): S262-S265.
27. Murakami, K. et al 1996. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 87: 642-647.
28. Yasui, H. et al 2001. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am. J. Respir. Crit. Care Med. 163: 1660-1668.
29. Shibata, M. et al 2001. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation 103: 1799-1805.
30. Lay, A.J. et al 2005. Mice with a severe deficiency in protein C display prothrombotic and proinflammatory phenotypes and compromised maternal reproductive capabilities. J. Clin. Invest. 115: 1552-1561.
31. Lay, A.J. et al 2007. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 109: 1984-1991.
32. Feistritzer, C. & M. Riewald 2005. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105: 3178-3184.
33. Feistritzer, C. et al 2003. Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C. J. Allergy Clin. Immunol. 112: 375-381.
34. Finigan, J.H. et al 2005. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J. Biol. Chem. 280: 17286-17293.
35. Zeng, W. et al 2004. Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit. Care Med. 32(5 Suppl): S302-S308.
36. Sadlack, B. et al 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261.
37. Shimizu, S. et al 2003. Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am. J. Respir. Crit. Care Med. 167: 1416-1426.
38. Stephenson, D.A. et al 2006. Modulation of monocyte function by activated protein C, a natural anticoagulant. J. Immunol. 177: 2115-2122.
39. Galligan, L. et al 2001. Characterization of protein C receptor expression in monocytes. Br. J. Haematol. 115: 408-414.
40. Joyce, D.E., D.R. Nelson & B.W. Grinnell 2004. Leukocyte and endothelial cell interactions in sepsis: relevance of the protein C pathway. Crit. Care Med. 32(5 Suppl): S280-S286.
41. Sturn, D.H. et al 2003. Expression and function of the endothelial protein C receptor in human neutrophils. Blood 102: 1499-1505.
42. Franscini, N. et al 2004. Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation 110: 2903-2909.
43. Joyce, D.E. et al 2001. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276: 11199-11203.
44. Joyce, D.E. & B.W. Grinnell 2002. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit. Care Med. 30(5 Suppl): S288-S293.
45. Riewald, M. & W. Ruf 2005. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J. Biol. Chem. 280: 19808-19814.
46. Cheng, T. et al 2003. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat. Med. 9: 338-342.
47. Joyce, D.E. et al 2001. Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276: 11199-11203.
48. Liu, D. et al 2004. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat. Med. 10: 1379-1383.
49. Mosnier, L.O. & J.H. Griffin 2003. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem. J. 373(Pt 1): 65-70.
50. Hotchkiss, R.S. et al 2000. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat. Immunol. 1: 496-501.
51. Feistritzer, C. et al 2006. Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J. Biol. Chem. 281: 20077-20084.
52. Minhas, N. et al 2009. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J 24: 873-881.
53. Bae, J.S. et al 2007. Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties. J. Biol. Chem. 282: 9251-9259.
54. Niessen, F. et al 2008. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 452: 654-658.
55. Shao, L., D. Serrano & L. Mayer 2001. The role of epithelial cells in immune regulation in the gut. Semin. Immunol. 13: 163-176.
56. Yu, Y., S. Sitaraman & A.T. Gewirtz 2004. Intestinal epithelial cell regulation of mucosal inflammation. Immunol. Res. 29: 55-68.
57. Matter, K. & M.S. Balda 2003. Signalling to and from tight junctions. Nat. Rev. Mol. Cell Biol. 4: 225-236.
58. Schneeberger, E.E. & R.D. Lynch 2004. The tight junction: a multifunctional complex. Am. J. Physiol. Cell Physiol. 286: C1213-C1228.
59. Danese, S. & C. Fiocchi 2006. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol. 12: 4807-4812.
60. Schmitz, H. et al 2000. Epithelial barrier and transport function of the colon in ulcerative colitis. Ann. N.Y. Acad. Sci. 915: 312-326.
61. Katz, K.D. et al 1989. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 97: 927-931.
62. Adenis, A., et al 1992. Increased pulmonary and intestinal permeability in Crohn's disease. Gut 33: 678-682.
63. Hollander, D. et al 1986. Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann. Intern. Med. 105: 883-885.
64. Gitter, A.H. et al 2001. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 121: 1320-1328.
65. Guihot, G. et al 2000. Inducible nitric oxide synthase activity in colon biopsies from inflammatory areas: correlation with inflammation intensity in patients with ulcerative colitis but not with Crohn's disease. Amino Acids 18: 229-237.
66. Ma, T.Y. et al 2004. TNF-alpha-induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G367-G376.
67. Heller, F. et al 2005. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129: 550-564.
68. Blair, S.A. et al 2006. Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest 86: 191-201.
69. Zolotarevsky, Y. et al 2002. A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 123: 163-172.
70. Su, L. et al 2009. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 136: 551-563.
71. Irving, P.M., K.J. Pasi & D.S. Rampton 2005. Thrombosis and inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 3: 617-628.
72. van Bodegraven, A.A. et al 2001. Hemostatic imbalance in active and quiescent ulcerative colitis. Am. J. Gastroenterol. 96: 487-493.
73. Yamamoto, K. & D.J. Loskutoff 1998. Extrahepatic expression and regulation of protein C in the mouse. Am. J. Pathol. 153: 547-555.
74. Xue, M., D. Campbell & C.J. Jackson 2007. Protein C is an autocrine growth factor for human skin keratinocytes. J. Biol. Chem. 282: 13610-13616.
75. Xue, M. et al 2004. Activated protein C stimulates proliferation, migration and wound closure, inhibits apoptosis and upregulates MMP-2 activity in cultured human keratinocytes. Exp. Cell Res. 299: 119-127.
76. Bae, J.S., L. Yang & A.R. Rezaie 2007. Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc. Natl. Acad. Sci. USA 104: 2867-2872.
77. Ishii, H. & P.W. Majerus 1985. Thrombomodulin is present in human plasma and urine. J. Clin. Invest. 76: 2178-2181.
78. Poritz, L.S. et al 2007. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J. Surg. Res. 140: 12-19.
79. Vetrano, S. et al 2008. Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. Gastroenterology 135: 173-184.
80. Young, N. & J.R. Van Brocklyn 2006. Signal transduction of sphingosine-1-phosphate G protein-coupled receptors. ScientificWorldJournal 6: 946-966.
81. Rosen, H. et al 2007. Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol. 28: 102-107.
82. Whitmont, K. et al 2008. Treatment of chronic leg ulcers with topical activated protein C. Arch. Dermatol. 144: 1479-1483.
83. Lichtnekert, J. et al 2011. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice. J. Immunol. 187: 3413-3421.